A Phase I/II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of SB 240683 in Patients With Symptomatic Steroid-Naive Asthma

Facet Biotech18 sites in 1 country120 target enrollmentAugust 2001

ConditionsAsthma

Drugsanti-IL-4 monoclonal antibody (pascolizumab)

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Asthma
Sponsor: Facet Biotech
Enrollment: 120
Locations: 18
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate an investigational medication to treat chronic asthma. The research is being conducted at 20 clinical research sites in the US and is open to both men and women ages 18 to 70 years. Participants in the study will have a number of visits to a research site over an 8-month period. All study-related care and medication is provided to qualified participants at no cost. This includes all visits, examinations and laboratory work.

Registry

clinicaltrials.gov

Start Date

August 2001

End Date

February 2003

Last Updated

14 years ago

Study Type

Interventional

Study Design

Parallel